Differences in clinical and laboratory biomarkers for short and long‐term respiratory outcomes in preterm neonates
- 26 August 2021
- journal article
- research article
- Published by Wiley in Pediatric Pulmonology
- Vol. 56 (12) , 3847-3856
Abstract
Background: Pulmonary outcome of premature neonates has focused more on short‐term than long‐term respiratory morbidities.Objective: Describe risk factors/biomarkers associated with short‐term (bronchopulmonary dysplasia [BPD]) (supplemental oxygen use at 36 weeks postmenstrual age [PMA]) and longer‐term (chronic respiratory morbidity [CRM]) (respiratory related symptoms, medications, medical/emergency visits, hospitalizations at 6–12 months corrected gestational age [CGA]) respiratory outcomes in a longitudinal cohort.Design/Methods: Neonates born at 24–29‐week gestation were prospectively followed to 6–12‐month CGA. Associations between clinical and laboratory risk factors/biomarkers of BPD and CRM were explored.Results: Of 86 subjects, 94% survived. Outcomes were available for 89% at 36‐week PMA (BPD present in 42% of infants) and 72% at 6–12‐month CGA (CRM present in 47% of infants). For the 54 infants with known outcomes for both BPD and CRM, diagnoses were discordant in 41%. BPD was associated with lower birthweight and birthweight Z‐score for GA, lower Apgar scores, more surfactant doses, higher SNAPPE‐II scores, highest Day 1 inspired oxygen concentration, Day 7 oxygen use, prolonged ventilatory support, bacteremia, necrotizing enterocolitis, and treated patent ductus arteriosus. CRM was associated with lower Apgar scores, Day 7 oxygen use and higher urine vascular endothelial growth factor. Patterns of plasma and urine lipid oxidation products differed in the two outcomes.Conclusion: In this hypothesis generating and exploratory study, BPD and CRM were associated with different risk factors/biomarker patterns. Concordance between these two outcomes was weak. Strategies for reducing CRM should be studied in cohorts identified by appropriate early risk factors/biomarkers.Keywords
Funding Information
- National Institutes of Health (UL1RR025752 ARRA Supplement 1C76HF15064‐01‐00, UL1RR025758, UL1TR002544)
This publication has 32 references indexed in Scilit:
- Low Urine Vascular Endothelial Growth Factor Levels Are Associated with Mechanical Ventilation, Bronchopulmonary Dysplasia and Retinopathy of PrematurityNeonatology, 2013
- Hyperoxia Exposure Alters Hepatic Eicosanoid Metabolism in Newborn MicePediatric Research, 2010
- Epidemiology of bronchopulmonary dysplasiaSeminars in Fetal and Neonatal Medicine, 2009
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Bronchopulmonary dysplasia: pathway from disease to long-term outcomeJournal of Perinatology, 2008
- Risk factors for uteroplacental vascular compromise and inflammationAmerican Journal of Obstetrics and Gynecology, 2008
- Validation of the National Institutes of Health Consensus Definition of Bronchopulmonary DysplasiaPediatrics, 2005
- Impact of a Physiologic Definition on Bronchopulmonary Dysplasia RatesPediatrics, 2004
- Safety, Reliability, and Validity of a Physiologic Definition of Bronchopulmonary DysplasiaJournal of Perinatology, 2003
- Urine Bombesin-like Peptide Elevation Precedes Clinical Evidence of Bronchopulmonary DysplasiaAmerican Journal of Respiratory and Critical Care Medicine, 2002